LIXTE Biotechnology Reports Encouraging Interim Results for Ovarian Cancer Combination Therapy

LIXTE Biotechnology Holdings presented interim results from a clinical trial evaluating its proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference. Data from 20 evaluable patients showed a 40% disease control rate and encouraging survival trends with an acceptable safety profile, supporting continued enrollment of an expanded cohort.

The company is investigating the combination’s potential to enhance immunotherapy response in ovarian clear cell carcinoma, a particularly aggressive form of ovarian cancer that often shows poor response to conventional treatments. LB-100 represents a first-in-class clinical PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity.

Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The compound is part of a pioneering effort in an entirely new field of cancer biology called activation lethality, which is advancing a new treatment paradigm. Additional information about the company’s research can be found at https://www.lixte.com.

LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma. The company’s wholly owned subsidiary, Liora Technologies Europe Ltd., is also developing electronically controlled proton therapy systems for treating tumors in various types of cancers. More information about this technology is available at https://www.lioratechnologies.com.

The interim results represent an important step in addressing the significant unmet medical need in ovarian clear cell carcinoma treatment. The disease control rate observed in this early-stage trial suggests potential for the combination therapy to provide meaningful clinical benefit for patients who often have limited treatment options. The acceptable safety profile reported supports further investigation of this therapeutic approach.

As the trial continues with expanded enrollment, researchers will gather additional data to better understand the combination’s efficacy and safety characteristics. The findings presented at the gynecologic oncology conference contribute to the growing body of evidence supporting novel approaches to cancer treatment that target specific biological mechanisms to enhance existing therapies.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is LIXTE Biotechnology Reports Encouraging Interim Results for Ovarian Cancer Combination Therapy.

The post LIXTE Biotechnology Reports Encouraging Interim Results for Ovarian Cancer Combination Therapy appeared first on citybuzz.